Wang Feng-Ming's sale of 6,086 shares on September 17, 2026, deserves scrutiny, even if the explanation is routine. The Ambarella Inc. CEO offloaded approximately $394,555 in stock at $64.83 per share to cover tax obligations from restricted stock unit vesting—a common and defensible reason. Yet the timing raises questions. Ambarella's stock has cratered roughly 26% over the past year and currently trades at $63.12, down from where Wang sold his shares just one day earlier. For a leader who presumably believes in his company's future, the decision to sell at all, even for taxes, sends an unambiguous signal about confidence.
The contradiction between Wang's actions and Wall Street's enthusiasm is impossible to ignore. Ambarella just posted second-quarter fiscal 2027 results that beat expectations, with revenue of $108.1 million against forecasts of $107.76 million and non-GAAP earnings per share of $0.18 versus anticipated $0.17. By most measures, this is a win. Yet the company simultaneously warned investors about margin pressure and memory-supply uncertainty—the kind of headwinds that don't appear in a single quarter's results but linger for years.
The analyst community remains sharply divided on what comes next. Rosenblatt issued a Buy rating with a $120.00 price target following Ambarella's launch of its X7 standalone AI accelerator, suggesting substantial upside from current levels. However, Stifel downgraded its price target from $106 to $90, acknowledging valuation compression across the semiconductor industry while maintaining a Buy rating—a contradictory stance that essentially admits the fundamentals may not justify current valuations. Oppenheimer's Perform rating falls somewhere between optimism and caution, adding to the fog.
InvestingPro's analysis that Ambarella appears undervalued at current levels does little to resolve the disconnect. Undervaluation and value traps wear identical masks; the distinction only emerges in hindsight. Wang retains beneficial ownership of 767,759 ordinary shares—a stake that would presumably grow significantly if the stock reaches Rosenblatt's $120 target. Yet he still chose to sell.
Investors should be wary of the narrative that recent deals with Capgemini and Macnica, combined with the X7 accelerator launch, guarantee a recovery. Ambarella's challenges are real: margin pressure and supply uncertainty are not minor concerns in semiconductors, and a 26% annual decline reflects more than temporary market weakness. Before backing the bull case, demand clarity on when margins will stabilize and how the company plans to navigate ongoing supply constraints. Wang's willingness to sell, despite his outsized upside if the stock recovers, suggests he knows something the most optimistic analysts may have missed.